ZERO Biotech is developing novel radiotracers (including small molecules, peptides & antibodies) and advanced radiopharmaceuticals to advance cancer care. These novel technologies can seek out specific biomarkers only found on certain cancer types which further enhance imaging usages such as early diagnosis and target those hard-to-treat cancer tumors such as neuroendocrine tumors, lung cancer, prostate cancer, thyroid cancer, gastrointestinal cancers, colorectal cancer and sarcomas in the foreseeable future. The field of research is important because it is also the road to personalize medicinal treatment based on each patient's unique stage of cancer status, health situations and symptoms.